FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer

FDA medical oncologists discuss the agency’s accelerated approval of rucaparib for treatment of patients with advanced ovarian cancer.
ReachMD Healthcare Image
Media formats available
  • Completing the pre-test is required to access this content.
    Pre-Survey
    Completing the pre-survey is required to access this content.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free